17/02/2017 15:57:22

INNL INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Innocoll Holdings plc and a Lead Plaintiff Deadline of March 27, 2017

NEW YORK, Feb. 17, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Innocoll Holdings plc (NASDAQ:INNL) securities between November 3, 2016 through December 29, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/innocoll-holdings-plc. There is no cost or obligation to you.

According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Innocoll you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/innocoll-holdings-plc.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.

39 East Broadway

Suite 304

New York, NY 10002

Tel. 212.425.1140

Fax. 866.699.3880

E-Mail: vw@wongesq.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Aug
PNDORA
  Jeg har løbende adgang til Carnegies analyser af Pandora og har senest i dag modtaget seks slides,..
55
18 Aug
VWS
Normal 0 false false false DA X-NONE X-NONE ..
32
16 Aug
BAVA
Kære Bavarian aktionærer jeg har forsøgt at samle lidt informationer sammen dels taget fra ”sodazare..
23
17 Aug
 
Hvis du ikke kan tåle -1,5% uden at skulle skrive et indlæg om at gå kontant, er aktiemarkedet for h..
21
15 Aug
VWS
Hej Per.   1) Når et selskab køber aktier bliver de en del af virksomhedens ejendom - de kan derfor ..
15
15 Aug
VWS
Stop nu dig selv menneske. Du har tudet og vrælet op om, hvor elendigt kursen har ageret siden oktob..
14
16 Aug
NOVO-B
Jeg synes lige at I skal læse disse kloge ord:   For those of you who watch what you eat. Here’s the..
13
19 Aug
BAVA
For pokker det bliver interessant hvad de har af opdateringer. Vi ved de har lovet opdatering på Pro..
12
17 Aug
VWS
Jamen Herregud da. Er det et svaghedstegn, at Vestas performer i henhold til deres egen guidence?   ..
12
17 Aug
VWS
Der er tale om en forskydning af indtjenningen mellem 2 og 3 kvt. 2017 i forhold til 2016. 3. kvt. b..
12

Form 8.5 (EPT/RI) - Tesco plc

21/08/2017 07:43:02
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

18/08/2017 15:36:47
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Prima BioMed Appoints Non-Executive Director to the Board
2
Gamers Get First Chance to Play Xbox One X at GameStop Expo
3
Saniona AB: Saniona's partner, Medix, initiates Phase 3 study for tesofensine in obesity
4
Cecilie B. Heuch appointed EVP and Chief People Officer of Telenor Group
5
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 August 2017 13:02:02
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170808.1 - EUROWEB2 - 2017-08-21 14:02:02 - 2017-08-21 13:02:02 - 1000 - Website: OKAY